Introduction
Glaucoma is an optic neuropathy characterized by the progressive loss of retinal ganglion cells. The clinical features are thinning of the nerve fiber layer and excavation of the optic nerve head caused by the depletion of ganglion cell axons. As a consequence, patients develop characteristic scotomas in their visual field examinations. If left untreated, glaucoma can progress to complete blindness. In the United States, approximately 2-3% of Caucasians and 8-10% of African-Americans will acquire glaucoma in their lifetime. 1, 2 An elevation in intraocular pressure (IOP) is the most important risk factor for glaucoma. 3 On average, IOPs above 21 mmHg are considered high and patients who meet this criterion are followed for glaucomatous changes to their optic nerve and/or visual field. Although not considered the disease itself, elevated IOP is the single parameter amenable to intervention and its reduction is the only accepted treatment for glaucoma.
Recent reports from the Advanced Glaucoma Intervention Study 4 indicate that IOP must be lowered substantially and consistently to halt the progression of glaucomatous damage. Medical therapy is usually the initial treatment to lower IOP, either by reducing the production of aqueous humor by the ciliary body or by increasing outflow facility. If medical therapy fails, patients are treated with either laser therapy or trabeculectomy surgery. Of the three available options, surgery has been reported to achieve the greatest reduction in IOP and, thus, is most likely to preserve visual function. [5] [6] [7] Trabeculectomy surgery lowers IOP by creating a fistula through the sclera at the limbus into the anterior chamber. This permits aqueous to drain into the subconjunctival space, creating an elevated bleb of Tenon's capsule and conjunctiva. Aqueous in the bleb is then reabsorbed by surrounding tissues. There were an estimated 145 000 trabeculectomy surgeries performed in the United States in 1996 based on records from the National Hospital Discharge Survey and the National Survey of Ambulatory Surgery. The success of trabeculectomy is varied because scarring of the conjunctiva can effectively close the fistula in some eyes. Pulse labeling studies in non-human primates indicate that the major proliferative stage of the wound healing response occurs during the first 2 weeks postoperatively. 8 To inhibit the proliferative stage of the wound healing response and prevent surgical failures, surgeons have incorporated the adjunctive use of antimetabolites during the procedure, most commonly 5-fluoro-uracil or mitomycin C (MMC). While effective, both have been associated with serious and sometimes blinding side effects including corneal epithelial defects, hypotony, thin-walled and leaking blebs caused by tissue breakdown, and/or endophthalmitis. [9] [10] [11] [12] [13] In addition, with adjunctive MMC use approaching 20 years, late-onset complications are becoming more apparent. 13 This increased risk of side effects has prompted investigations into alternative adjunctive agents with less aggressive antiproliferative effects and a safer profile. These agents block different aspects of the wound healing cascade including the initial signaling events, 14, 15 cell proliferation, 16 and cell migration. 17 Recently, antiproliferative gene therapy has been used adjunctively with glaucoma surgery in animal models. We used a recombinant adenovirus (rAd) to introduce the human gene for p21 WAF-1/cip-1 (p21) into rabbit Tenon's fibroblasts in a normotensive model of glaucoma surgery. 18 This transgene product normally blocks entry of dividing cells into S phase of the cell cycle by antagonizing the activity of several cyclin-dependent kinases. 19, 20 The expression of p21 in the rabbit model persisted for more than 2 weeks after transduction and was as effective as MMC at reducing IOP and preventing fibroproliferation over a 4-week period. Unlike MMC, however, the p21 gene therapy produced no toxic effects in rabbits. Here, we extend the investigation of p21 gene therapy in glaucoma filtration surgery, demonstrating long-term control of IOP in a non-human primate model of experimental glaucoma when used in combination with trabeculectomy surgery. In addition, consistent with our observations in rabbits, there were no significant complications associated with its use.
Results

Regulation of IOP by rAd-p21
Success of trabeculectomy surgery is often judged on the basis of maintaining IOP at a low target level. Similarly, the ability of antiproliferative agents to prevent wound healing can be evaluated as a function of the success at maintaining this lowered IOP. Surgeries conducted without an adequate antiscarring agent would initially be successful at lowering IOP, but as the wound healed the IOP would again increase. To test the ability of rAdp21 to control wound healing in a model of ocular hypertension, IOP was elevated in one eye of each monkey by laser scarification of the trabecular meshwork (TM) and then lowered by trabeculectomy surgery. Adjunctive agents used in this surgery included rAdp21, a recombinant adenovirus without a transgene (rAd-control), MMC, and balanced saline solution (BSS). Table 1 summarizes the mean IOP history of each eye for each animal in the study both before and after surgery. The average IOP of control eyes (n ¼ 16) was 15.571.8 mmHg (mean7s.d.) before surgery and 16.671.4 mmHg after. All but two animals exhibited an elevation in IOP in the experimental eyes in the period prior to surgery (mean elevated IOP was 32.079.25 mmHg). Of the four groups, BSS-treated animals exhibited the lowest mean elevated IOP in the experimental eyes prior to surgery (27.878.3 mmHg), followed by rAd-p21 animals (29.876.8 mmHg), MMC animals (33.6712.1 mmHg), and rAd-control animals (36.9710.1 mmHg). Of the two animals that never developed elevated IOP, one was treated with BSS during surgery (animal 11231) and the other was treated with MMC (animal 11301).
The ability to maintain a target IOP was determined using both objective and subjective criteria. For the objective analyses, IOP was evaluated in two ways: Two eyes that were operated on did not have elevated IOP prior to surgery (*) even after complete photocoagulation of the TM. Treatment groups included BSS, MMC, rAd-p21, and rAd-control.
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(1) postsurgical mean IOP comparing the experimental eye and contralateral control eye (Table 1) , and (2) evaluation of the proportion of time the IOP in the experimental eye was less than or equal to the IOP of the control eye plus 2 mmHg (IOP exp p(IOP con þ 2 mmHg)). For this latter analysis, the postsurgical IOP history of each animal was evaluated for the entire period after surgery and also in trimesters of B86 days to enable comparisons between early and late effects. As postsurgical inflammation resulted in IOP spikes shortly after surgery in some animals, the data were evaluated starting at postsurgery day 11. The mean proportion of time the criterion was met for each group during the entire period or for individual trimesters was determined ( Figure 1 ). Eyes treated with rAd-p21 during surgery exhibited a greater proportion of time at the target IOP range compared with each group for the entire experiment and for nearly every trimester. This difference was statistically significant relative to rAd-control-treated eyes (entire period, P ¼ 0.0277; first trimester, P ¼ 0.0289; second trimester, P ¼ 0.0336; t-test), indicating a gene-specific effect for rAd-p21. Furthermore, there were no significant differences between BSS-and rAd-control-treated eyes at any time period, demonstrating the lack of nonspecific viral effects. MMC-treated eyes achieved a greater proportion of time at the target IOP compared to rAd-p21-treated eyes during the third trimester, although this difference was not statistically significant (P ¼ 0.6256). Surgical success may also be defined by a significant drop in IOP compared to preoperative levels regardless of any comparison with IOP of the control eye. Therefore, subjective criteria were also used to judge the success of each surgery. In this analysis, four glaucoma surgeons were asked to score successful reduction of IOP using graphs of IOP versus time for each animal. Individual scores, and the mean scores for each animal, are shown in Table 2 . Overall, there was close agreement among the surgeons for most of the cases. The mean scores for each treatment yielded similar findings to the statistical evaluation of the IOP data, in that rAd-p21 was more successful than any other group at maintaining IOP control over the duration of the experiment (Pp0.0025, t-test). Interestingly, rAd-control eyes, which were the least successful using a statistical criterion, were ranked second most successful in the subjective analysis, due to the pattern of the IOP response over time.
Clinical and histological evaluation of the surgical site
Slit-lamp examinations were conducted on each animal at regular intervals before and after surgery. These exams included a score for the presence of protein (flare) and cells in the anterior chamber. All eyes exhibited measurable flare during the first week after surgery. This was Gene therapy for glaucoma surgery G Heatley et al not associated with any particular treatment group (data not shown) and resolved within the first week postsurgery. Similarly, there were no associations between decreased vascularization of the bleb and treatment. Two eyes treated with MMC (11316 and 11301) showed progressive depigmentation of the blebs, indicating the loss of melanocytes, which are normally present in the monkey conjunctiva. Bleb morphology was different in this primate model than blebs formed in human eyes after surgery. The monkey blebs were flatter and less spread out, whereas blebs in humans are larger and more domed in shape. This difference may have been a function of the substantially thicker Tenon's capsule layer found in the monkey eyes. Analysis of both bleb extent (lateral size of the bleb) and height showed that surgery formed only small flat blebs that changed very little in size during the postoperative period (data not shown). There was no association found for differences in bleb morphology between the treatment groups. At the end of the postoperative period, histological sections of the surgical sites were evaluated by two masked ocular pathologists and scored for inflammation, fibroproliferation, a patent fistula into the anterior chamber, and overall bleb score ( Figure 2 and Table 3 ). Every experimental eye exhibited chronic granulomatous inflammation around the nylon suture used to close the scleral flap during surgery. All eyes also exhibited low to moderate levels of chronic nongranulomatous inflammation, but this was generally scored higher in eyes treated with recombinant adenovirus. None of the inflammation was considered clinically significant. The highest score for nongranulomatous inflammation was present in one of the eyes treated with rAd-p21 (animal 11064), which was likely caused by an abnormal The presence of fibrosis was assessed from sections stained for collagen deposition (Gomori trichrome). Fibrosis was consistently observed in BSS and rAdcontrol eyes, and was usually accompanied by the closure of the surgical fistula. MMC and rAd-p21 generally scored lower for fibrosis, although one of the rAd-p21-treated eyes (11138) showed evidence of extensive fibrosis along with cells of the iris pigment epithelium in the closed fistula.
MMC eyes had the highest overall score for bleb morphology and patent fistula (2.7571.26, mean7s.d., out of a possible score of 4), followed by rAd-p21-(2.071.15), BSS-(1.7570.96), and rAd-control-(1.570.58) treated eyes. MMC blebs all exhibited marked acellularity (Figure 2d) , consistent with its action of stimulating the apoptosis of Tenon's fibroblasts. In addition, connective tissue in Tenon's capsule and the scleral flap over the fistula showed signs of breakdown. Although none of the MMC-treated eyes developed any clinical complications, one eye (animal 11301) exhibited thinning of the conjunctiva with regions completely devoid of conjunctival epithelial cells (Figure 2f ). Lastly, there was only a loose correlation between the level of fibrosis and bleb morphology and the overall ability of the bleb to filter aqueous and control IOP. This was particularly evident in two of the p21-treated eyes (11046 and 11138), suggesting that even though the fistulas appeared closed at the light microscopic level, the tissue may still have been porous enough to allow drainage of fluid.
Discussion
Trabeculectomy surgery creates a fistula into the anterior chamber to allow the flow of aqueous fluid out of the eye. Success of this surgery is primarily defined as the ability to lower IOP for a substantial time, thus reducing the risk of glaucomatous damage to the optic nerve and retina. Wound healing is the primary reason for surgical failure, so the majority of operations are carried out with adjunctive antimetabolite therapy. Drugs used for this treatment provide effective prevention of wound healing, but are associated with deleterious side effects. We have been investigating the use of human p21 gene therapy as an antimetabolite in an effort to develop an effective treatment with fewer side effects.
Treatment of monkeys with ocular hypertension showed that surgery with rAd-p21 prevented wound healing and provided excellent control of IOP, even outperforming the MMC controls used in this experimental paradigm. Histologic analysis of the surgical sites also showed that both rAd-p21 and MMC prevented fibrosis, but p21-treated eyes exhibited less damage to the existing tissue surrounding the surgical site.
MMC treatment and IOP control in the primate model of glaucoma surgery
This study was designed with a cohort of monkeys using MMC as a positive control. This group of four animals yielded the highest score for bleb morphology and reduced fibrosis in the pathology findings, but also exhibited relatively poor IOP control based on both the statistical analysis and the scores from masked surgeons. Analysis of IOP data indicated that MMC-treated eyes did achieve lower IOPs, but only in the third trimester of the postoperative period. One explanation for this observation is that the fistula in some of the MMC eyes was blocked, perhaps from the scleral flap being sutured too tightly. This condition is reversed in humans by laser lysing or releasing one or more of the scleral sutures. In the monkeys, which did not undergo laser suture lysis, the blockage may have been relieved by the breakdown and dissolution of the scleral flap. This process has been termed 'melting' by glaucoma surgeons and is not uncommon in eyes treated with MMC. Histology of the MMC surgical eyes showed complete absence of the scleral flap, which supports this explanation.
Mechanisms of action of MMC and p21 correlate with the differences in postsurgical tissue damage MMC and p21 prevent fibrosis by different mechanisms.
Melting is a phenomenon that underlies the principal mechanism of MMC action. MMC prevents wound healing by stimulating widespread apoptosis, 21 which often leaves the tissue surrounding the surgical site extensively damaged 15 and acellular (Figure 2d and f). As a consequence, the scleral and conjunctival tissue is not able to renew itself from normal wear and tear, and subsequently breaks down over time leaving a fragile acellular sheath covering the entire surgical site. A high percentage of blebs created using MMC develop leaks because of this thinning, 9, 22, 23 which sometimes leads to the entry of infectious agents that can cause endopthalmitis. 10 An advanced stage of this thinning was present in one of our MMC-treated animals (Figure 2f) .
In contrast to MMC, p21 gene therapy targets the cell cycle without stimulating apoptosis in most cases, causing cell cycle arrest instead. 24, 25 This mechanism of action is typical for Tenon's fibroblasts in vitro, which become blocked at the G1-S interface when transduced with rAd-p21. 18 Furthermore, treatment of conjunctival tissue in situ with rAd-p21 leaves the tissue cellular with a substantial amount of the existing connective tissue remaining intact (Figure 2c and e) , leading to the speculation that the bleb will remain healthy for a longer time period after surgery.
Summary
Previous studies carried out on a rabbit model of glaucoma surgery 18 and this study on non-human primates both indicate that rAd-p21 gene therapy effectively prevents wound healing in this surgical paradigm. Both studies have also yielded complications associated with MMC use that are consistent with complications observed in some human cases. No such complications have been observed with the use of rAdp21, suggesting that it may be both an effective and safe alternative to MMC.
Materials and methods
Animals and the induction of ocular hypertension
Naïve Cynomologous monkeys (Macaca fascicularis) of approximately 8 years of age were purchased from Covance and used in this study. Animals were handled in accordance with the Association for Research in Vision and Ophthalmology Resolution on the use of animals for research and the guidelines for the use of non-human primates established by the University of Wisconsin. Eight males and eight females were randomly assorted into four groups of four. All animals received baseline evaluations that included photographs of their optic nerves and outflow facility measurements. Some animals were also tested using electrophysiology assays. The results of these studies will be reported elsewhere.
Ocular hypertension was induced by laser trabeculoplasty. 26 Briefly, animals were anesthetized with ketamine HCl (10 mg/kg) and a modified goniolens 27 was placed on one eye. In the initial session, a laser was used to ablate 1801 of the TM. IOP was monitored every day for 2-3 weeks thereafter. If IOP was not elevated after an initial treatment, laser trabeculoplasty was repeated one or two more times to further ablate the remaining TM. Animals were scheduled for surgery if they exhibited significantly reduced outflow facility and had a sustained elevated IOP. Two animals never developed elevated IOP even with complete ablation of the TM and no significant outflow facility. These animals were also used for surgery. Postsurgical follow-up for each animal is described below.
Trabeculectomy surgery
Following induction of general anesthesia (intramuscular ketamine HCl, 10 mg/kg, followed by intravenous sodium pentobarbital, 15 mg/kg), conventional trabeculectomy was performed in the superior quadrant. Following incision of the conjunctiva and Tenon's capsule approximately 8 mm from the superior corneal limbus, lysis of densely adherent Tenon's capsule was performed to the limit of the limbus and the scleral bed thoroughly cauterized. Pledgets of Weck-Cel sponges (5 Â 5 Â 1 mm 3 ) soaked in reagent were placed in the subconjunctival space for 5 min. The surgeon was masked as to the treatment. Upon removal of the pledget, the area was rinsed with BSS and a 2 Â 2 mm 2 half-thickness scleral trabeculectomy flap was created. A Kelly Descemet punch was used to create a wide ostomy, and a partial iridectomy was performed. The scleral flap was closed with two nylon sutures at each corner. Flow through the flap was ascertained by inflating the anterior chamber with BSS through a limbal paracentesis, and the conjunctival incision closed in a single layer with a running Vicryl suture. Antibiotic and steroid was applied topically after surgery.
Recombinant adenoviruses
The rAd-p21 recombinant adenovirus was described previously, 18 and essentially consisted of a human p21 coding region linked to the CMV immediate-early promoter. This recombinant gene was inserted into an E1a/E1b deleted region of the adenovirus genome as described previously. 28 The rAd-control adenovirus consisted of the identical adenovirus backbone and CMV promoter without a transgene coding region inserted into the construct.
Pre-and postsurgical follow-up schedule Animals were evaluated using the following procedures. Slit-lamp examinations were performed at regular intervals both pre-and postsurgery on animals anesthetized with ketamine HCl (10 mg/kg). Each exam consisted of a trained observer (GH, PK) scoring the anterior chamber Gene therapy for glaucoma surgery G Heatley et al for cells and flare, clarity of the cornea and lens, inflammation of the conjunctiva, status of the iris and fistula, and the morphology of the surgical bleb (including bleb height, size, and vascularity). IOP was measured every 7-10 days by 'minifield' Goldman applanation tonometry 29 using a Haag-Streit slit lamp. Some IOP measurements were also taken using a Tono-pen XL (Mentor Ophthalmics Inc., Norwell, MA, USA) and converted to actual mmHg based on a standard calibration curve. 30 Optic nerve photographs were taken on animals under ketamine and pentobarbital anesthesia using a Zeiss fundus camera (Thornwood, NY, USA). All animals received base line photographs of each eye and had a minimum of three photos taken of each eye at regular intervals (approx. 90 days) after surgery.
Statistical analysis
All data collected in this study were evaluated using StatView software (SAS Institute, Cary, NC, USA). Comparisons of means were tested using a one-paired Student's t-test. P-values of 0.05 or less were considered significant.
